# EDGAR Filing Document

**Accession Number:** 0001623526
**File Stem:** 0001193125-23-004192
**Filing Date:** 2023-1
**Character Count:** 27033
**Document Hash:** a3a9d295b80e8c66f2564e8482d9c70b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-004192.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001193125-23-004192

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Stoke Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001623526
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 471144582
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38938
- **FILM NUMBER:** 23516704

**BUSINESS ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** 781-430-8200

**MAIL ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASOthera Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141028

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 9, 2023

------

## Stoke Therapeutics, Inc.

#### (Exact Name of Registrant as Specified in its Charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38938** | **47-1144582** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **45 Wiggins Ave**<br>**Bedford, Massachusetts** | **01730** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (781) 430-8200

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0001 par value per share | STOK | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD.**  |

---

On January 9, 2023, Stoke Therapeutics, Inc., a Delaware corporation (the "Company"), posted an updated corporate presentation with additional information to its website, in advance of making a formal presentation of such information (the "Presentation") at the J.P. Morgan Healthcare Conference on January 10, 2023. The Company is furnishing a copy of the Presentation, a full copy of which is attached hereto as Exhibit 99.1.

The information furnished with this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

The Presentation provides a business update with respect to the anticipated timing of certain milestones, including the following:

*STK-001: Dravet Syndrome* 

• Data from patients treated with multiple doses of 45mg is expected in mid-2023;

• Data from patients treated with multiple doses of 70mg is expected in the second half of 2023; and

• The Company expects to complete Phase 1/2a in 2023 to enable a Phase 3 program in 2024.

*STK-002: Autosomal Dominant Optic Atrophy ("ADOA")* 

• Clinical Trial Application submission in the United Kingdom for planned Phase 1/2 study in patients with ADOA is expected in the first half of 2023 to enable the Company to start a Phase 1/2 study in 2024.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| Exhibit<br> Number | Description |
| 99.1 | [Presentation, dated as of January 2023.](d427248dex991.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |

---

#### Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the ability of STK-001 to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in non-seizure comorbidities at the indicated dosing levels or at all, the ability of STK-002 to treat the underlying causes of Autosomal Dominant Optic Atrophy, and the timing and expected progress of clinical trials, data readouts and presentations for STK-001 and STK-002. Statements including words such as "anticipate," "plan," "will," "continue," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval of, and ultimately commercialize its produce candidates; the timing of data readouts and interim and final results of preclinical and clinical trials; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; preliminary interim data readouts of ongoing trials may show results that change when such trials are completed; the Company's ability to fund development activities and achieve development goals into 2025; the Company's ability to protect its intellectual property; the direct and indirect impacts of the ongoing COVID-19 pandemic and its variants on the Company's business; and other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, its quarterly reports on Form 10-Q and the other documentation the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **STOKE THERAPEUTICS, INC.** | **STOKE THERAPEUTICS, INC.** |
| Date: January 9, 2023 | By: | /s/ Stephen J. Tulipano |
|  |  | **Stephen J. Tulipano** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 99.1

![](g427248ex99_1p1g1.jpg)

Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer st 41 Annual J.P. Morgan Healthcare Conference January 10, 2023© Copy© Copy right 20 ri23 ght S20 toke 23 Therape Stoke Therape utics utic1 s

------

![](g427248ex99_1p2g1.jpg)

Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. (Stoke or us) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Stoke or any officer, director, employee, agent or advisor of Stoke. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Information provided in this presentation speaks only as of the date hereof. Stoke assumes no obligation to publicly update any information or forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, subsequent events, or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the ability of STK-001 to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in non-seizure comorbidities at the indicated dosing levels or at all, the ability of STK-002 to treat the underlying causes of Autosomal Dominant Optic Atrophy (ADOA), and the timing and expected progress of clinical trials, data readouts and presentations for STK-001 and STK-002. Statements including words such as anticipate, plan, will, continue, expect, or ongoing and statements in the future tens are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause our results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: Stoke's ability to advance, obtain regulatory approval of, and ultimately commercialize its produce candidates; the timing of data readouts and interim and final results of preclinical and clinical trials; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; preliminary interim data readouts of ongoing trials may show results that change when such trials are completed; Stoke's ability to fund development activities and achieve development goals into 2025; Stoke's ability to protect its intellectual property; the direct and indirect impacts of the ongoing COVID-19 pandemic and its variants on Stoke's business; and other risks and uncertainties described under the heading Risk Factors in Stoke's Annual Report on Form 10-K for the year ended December 31, 2021, its quarterly reports on Form 10-Q and the other documentation Stoke files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this presentation, and we undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. By attending or receiving this presentation you acknowledge that you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made; you will be solely responsible for your own assessment of the market and our market position; and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of Stoke.© Copyright 2023 Stoke Therapeutics 2

------

![](g427248ex99_1p3g1.jpg)

OUR GOAL: Upregulate protein expression to treat the underlying cause of severe genetic diseases Stoke's pipeline offers potential first-in-class disease modifying new medicines for diseases caused by protein insufficiency STK-001 for STK-002 for Autosomal Rett syndrome, And beyond… Dravet syndrome Dominant Optic Atrophy Syngap1 syndrome ~6,500 additional genes (ADOA) with TANGO A severe and progressive Severe and rare genetic target signatures genetic epilepsy neurodevelopmental diseases The most common inherited optic nerve disorder© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 3 3

------

![](g427248ex99_1p4g1.jpg)

Advantages of Stoke's Approach vs. Other Genetic Approaches Selectively boosts expression No observed unwanted Utility across small and large only in tissues where the off-target genetic effects gene targets and mutations protein is normally expressed Does not Ability to control dose level Simple and scalable alter DNA and duration manufacturing© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 4 4

------

![](g427248ex99_1p5g1.jpg)

Nonsense mediated Nonsense mediated decay (NMD) exon decay (NMD) exon without TANGO-ASO with TANGO-ASO = 50% Increased functional functional protein expression protein© Copyright 2023 Stoke Therapeutics 5 5 NMD: nonsense-mediated decay

------

![](g427248ex99_1p6g1.jpg)

Dravet Syndrome: A Severe, Progressive Genetic Epilepsy 1 out of 16,000 ~35,000 85% babies are born with Dravet syndrome of cases caused by a people affected in the U.S., Canada, HAPLOINSUFFICIENCY Japan, Germany, France and the UK of the SCN1A gene of children and adolescents with Dravet Up to syndrome die before adulthood, due to RESULTING in 1 SUDEP , prolonged seizures, seizure- 20% related accidents or infections 50% Seizures are not adequately controlled in Dravet syndrome is not concentrated Na 1.1 protein V of people with in a particular geographic area or expression Dravet syndrome 90% ethnic group 1 Sudden Unexpected Death in Epilepsy Sources: 2018 Health Advances Report; Djémié et al., Molecular Genetics & Genomic Medicine, 2016; Lagae et al.,© Copyright 2023 Stoke Therapeutics 6 Developmental Medicine & Child Neurology, 2017; Nabbout et al., Orphanet Journal of Rare Diseases, 2013

------

![](g427248ex99_1p7g1.jpg)

Current Treatment Paradigm is Burdensome and Ineffective Most patients end up on 3 or more anti-seizure medicines (ASM) Clinician perspectives on current treatment options Dravet Syndrome Treatment "Eliminating seizures is not possible. We strive for balance Diagnosis between seizure frequency, duration, and quality of life. Parents tolerate more seizures if it enables normal social activity." st 1 Line ASM 1 (4-8 weeks) "Patients are never well-controlled on one drug. After ASM 1 nd 2 Line a month or two establishing efficacy, dosing, and comfort, Add on (4-16 weeks) we always add at least a second." ASM 2 Add on Switch ASM 1 ASM 2 ASM 1 "ASMs are notorious for side effects, which is a big reason rd 3 Line ASM 2 ASM 3 ASM 3 (1-6 months) we switch drugs so frequently." ASM 3 Add on Add on Add on Switch Switch Switch th 4 Line (1-6 months) And© Copyright 2023 Stoke Therapeutics 7 beyond…

------

![](g427248ex99_1p8g1.jpg)

Our Goal: Transform the Treatment of Dravet Syndrome by Targeting the Underlying Cause of the Disease, Not Just the Seizures Multiple medicines available for No medicines available for Seizure management Syndrome management Available medicines used to control seizures: STK-001 • Acetazolamide• Felbamate• Rufinamide • Benzodiazepines• Fenfluramine• Stiripentol The only potential disease-modifying • Brivaracetam• Lamotrigine• Topiramate • Cannabidiol• Levetiracetam• Valproate products approach currently in the clinic • Carbamazepine• Mesuximide• Zonisamide • Clobazam• Oxcarbazepine • Ethosuximide• Phenytoin Despite these treatments, seizures are not adequately controlled in 90% of patients© Copyright 2023 Stoke Therapeutics 8

------

![](g427248ex99_1p9g1.jpg)

Our entire life has been impacted by this diagnosis. Our family has been disrupted. Our livelihood has been impacted. " " Our future is unknown, and the unknown can be so consuming. – Jennifer MK., Mom of Daughter with Dravet syndrome Voice of the Patient Report Published by the Dravet Syndrome Foundation, May 2022© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 9 9

------

![](g427248ex99_1p10g1.jpg)

Dravet Syndrome is More Than "Just Seizures" Movement & Balance Intellectual Disability & Developmental Delays "We're disappointed when [our son's] physical activity is limited and the short "Over time, we have seen slow, steady walk or visit that we plan with his decline in all areas, from speech, to mobility, grandmothers must now be changed to a endurance, loss of energy, tolerance for longer wheelchair ride." stimulation, stamina, etc." Language & Speech Sleep Abnormalities Disturbances "Every single night, he has seizures in his sleep. In addition to all of the other comorbidities of "At age 19, [our son] stopped talking, DS, he's robbed of the basic human necessity seemingly losing his capacity for speech of getting a good night's sleep. This impacts our overnight. Most days he is silent, and though entire family, as it is hard to function on he can understand simple conversation he is so little sleep day after day. largely unable to express himself."© Copyright 2023 Stoke Therapeutics 10 Source: Voice of the Patient Report Published by the Dravet Syndrome Foundation, May 2022

------

![](g427248ex99_1p11g1.jpg)

Potential disease-modifying gene therapies in SCN1A-positive Dravet syndrome….include antisense oligonucleotide (STK-001)…are positioned to improve not only seizure control, but by targeting the underlying cause and restoring native " " gene expression, could also address the equally important comorbidities that so often negatively impact patients living with epilepsy. – Joseph E. Sullivan, M.D., Professor of Neurology and Pediatrics and Director of the Pediatric Epilepsy Center of Excellence at the University of California San Francisco, and a prominent researcher into Dravet syndrome Genetic Testing in Patients With Epilepsy May Impact Treatments and Improve Outcomes, Sullivan, JAMA Neurology, 2022© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 11 11

------

![](g427248ex99_1p12g1.jpg)

Preclinical Findings Support Disease Modifying Potential of STK-001 Significant reductions in premature mortality and seizure frequency in DS mice after a single dose Single dose restores Na 1.1 V p<0.0001 to near-normal levels for ✓ >3 months in DS mice PBS wild-type (n=46) STK-001 wild-type (n=27) Achieves broad distribution +/- STK-001 SCN1a (n=34) and increases Na 1.1 protein ✓ V +/- PBS SCN1a (n=62) expression in NHPs NHP toxicology studies support current clinical ✓ dosing Postnatal days Sources: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci. Transl. Med. 12, eaaz6100 (2020). Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A reduces seizures and rescues parvalbumin positive interneuron firing frequency© Copyright 2023 Stoke Therapeutics 12 12 in a mouse model of Dravet syndrome (AES 2020). TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate (AES 2019). Survival (%)

------

![](g427248ex99_1p13g1.jpg)

Reductions in Convulsive Seizure Frequency Observed in Patients Treated With STK-001 On Top of Multiple Anti-Seizure Medicines All Ages Combined by Cohort 0 -15 -20.1% (n=17) -30 -40.6% (n=4) -45 20mg 30mg 45mg -55.2% (n=6) -60 Day 29 to 140 or 168 >50% of patients were taking concomitant fenfluramine© Copyright 2023 Stoke Therapeutics 13 Source: MONARCH and ADMIRAL Interim Analyses: Phase 1/2a Studies Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS) (AES 2022). Median % Change from Baseline

------

![](g427248ex99_1p14g1.jpg)

Reductions in Convulsive Seizure Frequency Observed Across Age Groups Taking Multiple Doses of STK-001 74% Median seizure reduction observed in younger patients 2-12y Combined by Cohort 13 - 18/<18y Combined by Cohort 0 0 -20.1% (n=7) -25 -25 -26.8% -23.4% (n=10) (n=2) -40.6% -39.7% (n=2) (n=4) -50 -50 -73.6% (n=2) -75 -75 Day 29 to 140 or 168 Day 29 to 140 or 168 20mg 30mg 45mg© Copyright 2023 Stoke Therapeutics 14 Source: MONARCH and ADMIRAL Interim Analyses: Phase 1/2a Studies Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS) (AES 2022). Median % Change from Baseline Median % Change from Baseline

------

![](g427248ex99_1p15g1.jpg)

67% (4/6) Patients Experienced >50% Reduction in Convulsive Seizure Frequency with Three Doses of STK-001 (45mg) Reductions began after the first dose and continued with additional treatment 50 50 45 mg MAD (n=6,6,6,6,6,4) 45 mg MAD 13-18/<18y 23.8 45 mg MAD 2-12y 0 0 -26.7 -50 -50 -52.8 -57.5 -72.5 -89.6 -100 -100 D1-28 D29-56 D57-84 D85-112 D113-140 D141-168 4/6 patients were taking concomitant fenfluramine Convulsive Seizure Frequency All Ages© Copyright 2023 Stoke Therapeutics 15 Source: MONARCH and ADMIRAL Interim Analyses: Phase 1/2a Studies Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS) (AES 2022). % Change from Baseline to Day 29-140/168 Median % Change from Baseline

------

![](g427248ex99_1p16g1.jpg)

Reductions in Seizure Frequency Were Maintained with Ongoing STK-001 Treatment Convulsive Seizure Frequency 50 25 0 -25 -50 -75 -100 Day Day Day Day Day Day Weeks Weeks Weeks Weeks Weeks Weeks Weeks Weeks 1-28 29-56 57-84 85-112 113-140 141-168 1-4 5-8 9-12 13-16 1-4 5-8 9-12 13-16 MONARCH Post Dose 1 Post Dose 2 Post Dose at D1 SWALLOWTAIL SWALLOWTAIL 30mg 30mg 30mg No exclusions for AED modification Source: SWALLOWTAIL: An Open-Label Extension (OLE) Study for Children and Adolescents with Dravet Syndrome (DS) who Previously Participated in a Study of Antisense© Copyright 2023 Stoke Therapeutics 16 Oligonucleotide (ASO) STK-001 (AES 2022). Median % Change from MONARCH Baseline in Convulsive Seizure Frequency (n=4)

------

![](g427248ex99_1p17g1.jpg)

Improvements in Non-Seizure Comorbidities Measured by the BRIEF-P Indicate the Potential for Disease Modification 20 20 No STK-001 All Doses = 30mg of STK-001 10 10 0 0 -10 -10 -20 -20 -30 -30 -40 -40 Week 16 (n=8) Week 32 (n=5) Overall (n=26) ISCI (Inhibit + Emotional Control) FI (Shift + Emotional Control) EMI (Working Memory + Plan/Organize) Global Executive Composite As measured by Behavior Rating Inventory of Executive Function–Preschool Version, an assessment of pediatric executive function. Sources: Twelve-month Analysis of BUTTERFLY: An Observational Study to Investigate Cognition and Other Non-seizure Comorbidities in Children and Adolescents with Dravet© Copyright 2023 Stoke Therapeutics 17 Syndrome (DS) (AES 2022). SWALLOWTAIL: An Open-Label Extension (OLE) Study for Children and Adolescents with Dravet Syndrome (DS) who Previously Participated in a Study of Antisense Oligonucleotide (ASO) STK-001 (AES 2022). Mean Change from Baseline to Month 12 (SD) Mean Change from Baseline (SD)

------

![](g427248ex99_1p18g1.jpg)

Summary of Key Ph1/2a Interim Data Single and multiple doses of STK-001 up to 45mg ✓ were well-tolerated 55% median reduction in convulsive seizure STK-001 Has Potential to frequency observed in patients treated with three ✓ doses of STK-001 (45mg) Address the Genetic Cause Reductions in seizure frequency were maintained of Dravet Syndrome ✓ with ongoing treatment Early indication of improvements in non-seizure ✓ comorbidities as measured by BRIEF-P\* \*Behavior Rating Inventory of Executive Function–Preschool Version, an assessment of pediatric executive function Sources: MONARCH and ADMIRAL Interim Analyses: Phase 1/2a Studies Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 18 18 Adolescents with Dravet Syndrome (DS) (AES 2022). SWALLOWTAIL: An Open-Label Extension (OLE) Study for Children and Adolescents with Dravet Syndrome (DS) who Previously Participated in a Study of Antisense Oligonucleotide (ASO) STK-001 (AES 2022).

------

![](g427248ex99_1p19g1.jpg)

Our Pipeline of First-in-Class Disease Modifying Potential Medicines PROGRAM TARGET DISCOVERY & PRECLINICAL PHASE 1/2 PHASE 3 PARTNER Central Nervous System 100% Stoke Dravet Syndrome SCN1A STK-001 Global Stoke : Acadia SYNGAP1 SYNGAP1 Syndrome 50:50 Acadia Rett Syndrome MECP2 Worldwide License Acadia Undisclosed Undisclosed Worldwide License Ophthalmology 100% Stoke OPA1 STK-002 ADOA Global© Copyright 2023 Stoke Therapeutics 19 ADOA: Autosomal dominant optic atrophy

------

![](g427248ex99_1p20g1.jpg)

2023 Priorities Develop & Expand Advance STK-001 for Advance STK-002 Pipeline Dravet Syndrome to Pivotal for ADOA • 45mg clinical data anticipated in • Submit CTA in the UK in the first • Expand TANGO ASOs as a first-in- mid-2023 half of 2023 to enable Phase 1/2 class disease-modifying approach start in 2024 for additional genetic diseases • 70mg clinical data anticipated in second half of 2023• Execute on collaboration with Acadia to advance Rett syndrome • Complete Phase 1/2a in 2023 to and Syngap1 syndrome programs enable a Phase 3 program in 2024© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 20 20 ADOA: Autosomal dominant optic atrophy

------

![](g427248ex99_1p21g1.jpg)

Current Liquidity Anticipated to Fund Operations into 2025 $252.2M 39.4M Cash, Cash Equivalents, Common Shares Outstanding Marketable Securities, and Restricted Cash as of 9/30/2022 as of 9/30/2022© Copy© Copyri right ght 20 2023 23 S Stoke toke Therape Therapeutic utics s 21 21

------

![](g427248ex99_1p22g1.jpg)© Copyright 2023 Stoke Therapeutics 22

------

![](g427248ex99_1p23g1.jpg)

Q&A© Copyright 2023 Stoke Therapeutics 23